EYEPOINT PHARMACEUTICALS

Serial Number 87821925
Registration 5875068
702

Registration Progress

Application Filed
Mar 6, 2018
Under Examination
Oct 2, 2018
Approved for Publication
Aug 7, 2018
Published for Opposition
Aug 7, 2018
Registered
Oct 1, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-10-01)
Due: Oct 01, 2025 58 days

Trademark Image

EYEPOINT PHARMACEUTICALS

Basic Information

Serial Number
87821925
Registration Number
5875068
Filing Date
March 6, 2018
Registration Date
October 1, 2019
Published for Opposition
August 7, 2018
Drawing Code
4

Status Summary

Current Status
Active
Status Code
702
Status Date
Feb 12, 2025
Registration
Registered
Classes
005 010

Rights Holder

EYEPOINT PHARMACEUTICALS US, INC.

03
Address
Suite C400
480 PLEASANT STREET, SUITE B300
WATERTOWN, MA 02472

Ownership History

pSivida US, Inc.

Original Applicant
03
Watertown, MA

EYEPOINT PHARMACEUTICALS US, INC.

New Owner Before Publication #1
03
WATERTOWN, MA

EYEPOINT PHARMACEUTICALS US, INC.

Owner at Publication
03
WATERTOWN, MA

EYEPOINT PHARMACEUTICALS US, INC.

Original Registrant
03
WATERTOWN, MA

Legal Representation

Attorney
Kimberly Jarman, Esq.

USPTO Deadlines

Next Deadline
58 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2019-10-01)
Due Date
October 01, 2025
Grace Period Ends
April 01, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

34 events
Date Code Type Description Documents
Feb 12, 2025 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Feb 12, 2025 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Feb 12, 2025 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Oct 3, 2024 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Oct 1, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Oct 28, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Oct 28, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 28, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 28, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Oct 28, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Oct 1, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 27, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Aug 26, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Aug 3, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 2, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 2, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 12, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 12, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 12, 2019 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Apr 7, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 7, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 22, 2019 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Mar 22, 2019 IUAF S USE AMENDMENT FILED Loading...
Oct 2, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 7, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 7, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 18, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 29, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 18, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 18, 2018 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Apr 18, 2018 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Apr 18, 2018 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 12, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 9, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease
First Use Anywhere: Feb 28, 2019
First Use in Commerce: Feb 28, 2019
Class 010
House mark for sustained drug delivery systems for pharmaceuticals
First Use Anywhere: Feb 28, 2019
First Use in Commerce: Feb 28, 2019

Additional Information

Pseudo Mark
EYE POINT PHARMACEUTICALS

Classification

International Classes
005 010

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"